secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cyclerion Therapeutics, Inc. (CYCN)
CIK:        0001755237
Form:       8-K
Filed at:   2021-09-30T23:59:59+00:00
Accession:  0001140361-21-033010
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cyclerion updates three CY6463 trials: CIAS Phase 1b enrolled, MELAS topline H1 2022, ADv screening
--------------------------------------------------------------------------------

- First patients enrolled in Phase 1b study of CY6463 for cognitive impairment associated with schizophrenia (CIAS).
- Phase 2a in MELAS remains enrolling; topline clinical results now expected in H1 2022.
- Patient screening started in Phase 2a study of CY6463 for Alzheimer's disease with vascular pathology (ADv).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1755237/000114036121033010/0001140361-21-033010-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1755237/000114036121033010/brhc10029438_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-21-033010

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer